LivaNova Reports Q2 2025 Earnings and Provides Business Update
LivaNova reported 10% organic revenue growth year-over-year, driven by cardiopulmonary and neuromodulation performance. Cardiopulmonary revenue reached $199 million, up 13% from Q2 2024, with full-year growth guidance raised to 12%-13%. The company highlighted supply chain constraints and regulatory uncertainties as potential risks.
Tickers: $LIVN
Topics: guidance market_share revenue_growth supply_chain tax_rate